経口固形製剤の追加剤形生物学的同等性免除に関する実践的洞察:主要規制当局の現在の要件と調和への道
Chandra Teja Uppuluri1, Adithya Karthik Bhattiprolu1, Anuj Kumar Saini1,2
1Biopharmaceutics Group, Global Clinical Management, Integrated Product Development Organization (IPDO), Dr. Reddy's Laboratories Ltd., Hyderabad, India.
Abstract:
Additional strength biowaivers offer a strategic advantage in pharmaceutical development by enabling regulatory approval of multiple strengths without separate bioequivalence (BE) studies. This review provides a comprehensive and timely analysis of current regulatory expectations for such waivers across major jurisdictions-USFDA (USA), EMA (Europe), HC (Canada), and ANVISA (Brazil)-for both immediate-release (IR) and modified-release (MR) solid oral dosage forms. The review also explores the evolving harmonisation efforts under the ICH M13A and draft M13B guidelines, highlighting their potential to streamline global submissions and reduce development complexity.Key scientific criteria such as pharmacokinetic linearity, formulation proportionality, and dissolution similarity are critically examined, with emphasis on how agency-specific interpretations influence regulatory outcomes.Several hypothetical case examples are presented to illustrate how regulatory decisions vary based on product-specific nuances and regional requirements. These examples provide practical insights into navigating scenarios, such as deviations in formulation proportionality or dissolution variability, and demonstrate how alternative statistical approaches can support biowaiver eligibility.By bridging current practices with future harmonised standards, this review serves as a valuable and timely resource for pharmaceutical professionals. It empowers developers to align strategies with both existing and emerging guidelines, facilitating efficient, multi-market drug development and regulatory compliance.
さらに関連する動画
11:27A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
05:08Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid
Published on: September 20, 2017
関連する概念動画
Bioequivalence studies: Biowaivers
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Drug Products: Biologics, Biosimilars and Interchangeables
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Factors Influencing Drug Absorption: Pharmaceutical Parameters
